Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemtuzumab Ozogamicin and Cytarabine in Older Patients With Untreated AML and High-Risk MDS
NCT00195000Phase 2Completed
- Sponsor
- Weill Cornell Medicine
- Start
- May 2003
- Primary completion
- May 2006
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemtuzumab ozogamicin in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Weill Cornell Medicine. Primary endpoint: Safety and efficacy of gemtuzumab ozogamicin in combination with cytarabine in inducing complete remission. Started May 2003; status: completed.
02
Drugs
gemtuzumab ozogamicin
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00195000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00195000.